Table 3.
Odds ratios (ORs) and 95% confidence intervals (CIs) of clinical status and AURKA rs2273535 genotype frequencies in 312 HCC patients.
| Variable | Genotypic frequencies | |||
|---|---|---|---|---|
| TT (N=152) | AT+AA (N=160) | OR (95% CI) | p value | |
| Clinical Stage | ||||
| Stage I/II | 95 (62.5%) | 118 (73.7%) | 1.00 | P=0.033* |
| Stage III/IV | 57 (37.5%) | 42 (26.3%) | 0.593 (0.367-0.960) | |
| Tumor size | ||||
| ≤ T2 | 96 (63.2%) | 119 (74.4%) | 1.00 | P=0.033* |
| > T2 | 56 (36.8%) | 41 (25.6%) | 0.591 (0.364-0.959) | |
| Lymph node metastasis | ||||
| No | 146 (96.1%) | 156 (97.5%) | 1.00 | P=0.472 |
| Yes | 6 (3.9%) | 4 (2.5%) | 0.624 (0.173-2.256) | |
| Distant metastasis | ||||
| No | 144 (94.7%) | 153 (95.6%) | 1.00 | P=0.714 |
| Yes | 8 (5.3%) | 7 (4.4%) | 0.824 (0.291-2.329) | |
| Vascular invasion | ||||
| No | 124 (81.6%) | 134 (83.8%) | 1.00 | P=0.613 |
| Yes | 28 (18.4%) | 26 (16.2%) | 0.859 (0.478-1.546) | |
| Child-Pugh grade | ||||
| A | 110 (72.4%) | 132 (82.5%) | 1.00 | P=0.033* |
| B or C | 42 (27.6%) | 28 (17.5%) | 0.556 (0.323-0.954) | |
| HBsAg | ||||
| Negative | 79 (52.0%) | 96 (60.0%) | 1.00 | P=0.496 |
| Positive | 73 (48.0%) | 64 (40.0%) | 0.898 (0.659-1.224) | |
| Anti-HCV | ||||
| Negative | 86 (56.6%) | 78 (48.8%) | 1.00 | P=0.099 |
| Positive | 66 (43.4%) | 82 (51.2%) | 1.320 (0.949-1.836) | |
| Liver cirrhosis | ||||
| Negative | 32 (21.1%) | 20 (12.5%) | 1.00 | P=0.045* |
| Positive | 120 (78.9%) | 140 (87.5%) | 1.867 (1.015-3.434) | |
The ORs with analyzed by their 95% CIs were estimated by logistic regression models.
> T2: multiple tumor more than 5 cm or tumor involving a major branch of the portal or hepatic vein(s)
* p value < 0.05 as statistically significant.